AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Prnewswire

Published November 10, 2026

MoreBetter Launches Co-Investment Program for Longevity, Peptide and Psychedelic Therapies

Read the full story at Prnewswire

psychedelic and ketamine therapies. The RWE Co-Investment Program is open to the providers, compounding pharmacies, clinics and brands that.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics